Methylphenidate

Psychostimulant, CNS stimulant, NDRI

Methylphenidate

Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR

Methylphenidate is a piperidine-derivative central nervous system stimulant and the most widely prescribed medicine for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine reuptake inhibitor — distinct from the amphetamines, which primarily release monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

• Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
• Narcolepsy
• Off-label: treatment-resistant depression (augmentation, especially in geriatric or medically ill patients), fatigue in advanced illness (cancer, HIV, multiple sclerosis), excessive daytime sleepiness in shift-work disorder

+ Add a problem

Titration strategies

Ritalin IR (children ≥6 y, adults): Start 5 mg PO twice daily (before breakfast and lunch); titrate by 5–10 mg/week. Max 60 mg/day in 2–3 divided doses. Ritalin LA / Metadate CD: 20 mg PO once daily AM; titrate by 10–20 mg weekly. Max 60 mg/day. Concerta (osmotic ER): Start 18 mg PO once daily AM. Titrate by 18 mg/week. Max 72 mg/day (adults); 54 mg/day (children). Daytrana (transdermal patch): Apply 10 mg/9 h patch to alternating hip 2 h before effect needed; remove after 9 h. Titrate weekly to max 30 mg/9 h. Focalin (d-methylphenidate): Use half the equivalent racemic dose. Narcolepsy: 10–60 mg/day in divided doses. Renal/hepatic impairment: caution; no specific adjustment guidelines but reduce dose and monitor.

+ Add a titration strategy

Effects

Therapeutic: improved attention, reduced impulsivity and hyperactivity, increased wakefulness, mild mood elevation, mild appetite suppression. Generally described as "smoother" and less euphoric than amphetamines at equivalent doses. Common adverse: decreased appetite, insomnia (especially with late dosing), headache, abdominal pain, mild irritability, dry mouth, mild elevation of heart rate and blood pressure, weight loss.

• Cardiovascular: tachycardia, mild–moderate hypertension; rare reports of sudden cardiac death in patients with structural heart disease (FDA warning)
• Psychiatric: anxiety, agitation, irritability, mood lability; rarely psychosis or mania (especially in patients with bipolar predisposition)
• Tics — methylphenidate can unmask or worsen motor/vocal tics; comorbid Tourette syndrome is a traditional but increasingly contested relative contraindication
• Dependence and misuse — Schedule II; oral therapeutic use has lower abuse liability than amphetamines, but crushed/insufflated/IV misuse is significant
• Growth suppression — modest reduction in height/weight velocity in chronically-treated children
• Priapism — rare but documented; FDA warning, especially in adolescents
• Peripheral vasculopathy — Raynaud-like phenomenon, rare digital ischemia
• Lowered seizure threshold — caution in epilepsy
• Lassitude / "crash" on withdrawal — fatigue, dysphoria, rebound hyperactivity
• Stereotyped behaviors — rare at therapeutic doses
• Skin reactions — chemical leukoderma (permanent depigmentation) at Daytrana patch application sites

+ Add an effect

Pharmacokinetics

Absorption: Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. Distribution: Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. Metabolism: Primarily metabolized by carboxylesterase 1 (CES1) in the liver — not by cytochrome P450 enzymes — to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated drug interactions, distinguishing it from amphetamines. Stereochemistry: Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate (Focalin) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. Elimination: ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.

Pharmacodynamics

Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is not a substrate for the transporters — it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.

Key effects:

• Affinity for DAT is roughly equal to or slightly greater than NET in binding studies, but functional consequences in prefrontal cortex are dominated by NET effects (because NET also clears dopamine in PFC).
• Minimal direct serotonergic activity at therapeutic doses.
• No meaningful MAO inhibition.
• No significant 5-HT, histamine, or muscarinic receptor binding.

The net therapeutic effect is enhanced catecholaminergic tone in prefrontal cortex (attention, executive function) and striatum (motor inhibition, reward processing), underlying both its therapeutic effects in ADHD and its abuse liability.

Interactions

• MAOIs (phenelzine, tranylcypromine, selegiline, linezolid) — hypertensive crisis risk; contraindicated
• Tricyclic antidepressants — methylphenidate may elevate TCA plasma levels; additive cardiovascular effects
• Warfarin / coumarins — methylphenidate may elevate INR
• Phenytoin, phenobarbital, primidone — methylphenidate may elevate anticonvulsant levels
• Antihypertensives — methylphenidate's pressor effect may partially antagonize
• Other sympathomimetics (pseudoephedrine, phenylephrine, decongestants) — additive cardiovascular effects
• Antipsychotics — pharmacologic antagonism (each may partially block the other's effects)
• Alcohol — may mask intoxication; may release more d-methylphenidate from racemic preparations via stereoselective metabolism
• Caffeine — additive stimulant and anxiogenic effects

Notably, few CYP-mediated interactions because methylphenidate is metabolized by CES1, not P450s — a clinical advantage over amphetamine when polypharmacy is a concern.

No interactions reported yet.

+ Add an interaction

Pregnancy and lactation

Category C. Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies — interpretation complicated by confounding by indication. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.

Monitoring

• Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use
• Consider ECG if cardiac risk factors are present
• At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
• Periodically reassess continued need; consider drug holidays in children to assess ongoing benefit and minimize growth-velocity effects
• Sleep quality and timing of last dose

  Patient counseling

• Take in the morning; avoid afternoon dosing to minimize insomnia.
• Do not crush, chew, or split extended-release tablets/capsules.
• Concerta: the osmotic tablet shell will appear intact in stool — this is normal and does not mean the medicine wasn't absorbed.
• Eat regular meals despite appetite suppression; weigh periodically.
• Stay well-hydrated.
• Do not combine with significant alcohol or other stimulants.
• Do not share or sell — Schedule II controlled substance; serious legal and clinical consequences.
• Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.
• Skin patches: rotate site daily to avoid persistent depigmentation; remove after 9 hours.
• Plan for the "crash" when the dose wears off — particularly with IR formulations late afternoon.
• If discontinuing after long use, expect a few days of fatigue and possible dysphoria.

  Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

See also

Mixed amphetamine salts, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine, Modafinil, Atomoxetine, Viloxazine

Summary

Classes

Psychostimulant, CNS stimulant, NDRI

Common uses

ADHD, narcolepsy

Pharmacy

Pharmacology

Routes

Oral, transdermal

Onset

20–60 min (oral)

Duration

IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time

Half-life

2–3 h (parent compound)

Bioavailability

~30% (high first-pass)

Pregnancy

Category C

Legal status

Schedule II

Purported mechanism

Norepinephrine–dopamine reuptake inhibition (DAT, NET)